Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia

[1]  S. Lauck,et al.  Drivers and outcomes of variation in surgical versus transcatheter aortic valve replacement in Ontario, Canada: a population-based study , 2022, Open Heart.

[2]  J. Ferrières,et al.  Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists , 2021, Journal of clinical medicine.

[3]  P. Valdivielso,et al.  Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study. , 2021, Atherosclerosis.

[4]  W. März,et al.  FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia , 2021, Scientific Reports.

[5]  G. Francis,et al.  Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) , 2021, The Lancet.

[6]  I. V. Van Gelder,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.

[7]  J. Ferrières,et al.  Screening and treatment of familial hypercholesterolemia in a French sample of ambulatory care patients: A retrospective longitudinal cohort study , 2021, PloS one.

[8]  J. Genest,et al.  Sex Differences in the Presentation, Treatment, and Outcome of Patients With Familial Hypercholesterolemia , 2021, Journal of the American Heart Association.

[9]  G. Gusto,et al.  Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients. , 2021, International journal of cardiology.

[10]  J. Ferrières,et al.  Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis , 2021, Medical science monitor : international medical journal of experimental and clinical research.

[11]  G. Tell,et al.  2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia. , 2020, Atherosclerosis.

[12]  M. Krempf,et al.  SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. , 2020, Atherosclerosis.

[13]  M. Krempf,et al.  An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals , 2020, European heart journal. Acute cardiovascular care.

[14]  G. Tell,et al.  Association of Low-Density Lipoprotein Cholesterol With Risk of Aortic Valve Stenosis in Familial Hypercholesterolemia. , 2019, JAMA cardiology.

[15]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[16]  J. Marrugat,et al.  Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients , 2019, Journal of clinical medicine.

[17]  J. Ferrières.  Hypercholesterolaemia and coronary artery disease: A silent killer with several faces. , 2019, Archives of cardiovascular diseases.

[18]  M. Krempf,et al.  High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. , 2018, Atherosclerosis.

[19]  J. Ruidavets,et al.  Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk , 2018, Clinical cardiology.

[20]  G. Watts,et al.  Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study) , 2017, Circulation.

[21]  G. Luc,et al.  The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients. , 2016, Journal of clinical lipidology.

[22]  B. Nordestgaard,et al.  Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. , 2016, European heart journal.

[23]  J. Ruidavets,et al.  Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population. , 2015, Archives of cardiovascular diseases.

[24]  J. Kastelein,et al.  Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. , 2015, JAMA.

[25]  M. Krempf,et al.  Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. , 2014, Atherosclerosis.

[26]  J. Ferrières,et al.  Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. , 1995, Circulation.